Vertex Secures Reimbursement Deal With NHS England for ALYFTREK® in Cystic Fibrosis Care
Tuesday, July 15, 2025
Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily combination therapy for cystic fibrosis (CF). This development follows a positive final draft recommendation from the National Institute for Health and Care Excellence (NICE).
ALYFTREK® is the latest in a series of CFTR modulators developed by Vertex and is authorised for use in patients aged six and above who have at least one F508del mutation or another responsive mutation in the CFTR gene.
The new treatment builds on previous therapies and aims to offer further improvement in health outcomes for people living with CF. It marks Vertex’s fifth approved treatment for the condition and is seen as an important step in enhancing long-term disease management.
With European regulatory approval now granted, patients in Ireland, Denmark, and Germany will be among the first in the European Union to gain access to the new medicine. Vertex also plans to continue discussions with other health authorities across the EU to make ALYFTREK® available to all eligible patients as quickly as possible.
